Experts solve mystery of ancient ‘mummified dragon' discovered by Japanese shogun
The 'dragon' has been stashed at the Shosoin Treasure House in the historic Japanese city of Nara, according to Pen News.
The remains were reportedly found by Yoshinori Ashikaga, a 15th-century shogun, in 1429.
Legend states that Ashikaga cut a piece from the Ranjatai, a rare and valuable piece of agarwood, at the time of the skeleton's discovery.
The shogun was visiting the Todai-ji temple in Nara at the time.
Shortly after, a monk at the temple claimed to have seen 'something in the shape of a small dragon' that was dried by the sun. Ashikaga took the skeleton and preserved it.
4 The remains were reportedly found by Yoshinori Ashikaga, a 15th-century shogun, in 1429.
Office of the Shosoin Treasure House
4 Researchers used X-ray technology and radiocarbon dating to date the marten back to the 11th or 12th centuries.
Office of the Shosoin Treasure House
But was the skeleton a dragon after all? Researchers say not quite.
A recently published study said the 'dragon' was actually a female Japanese marten.
The fluffy, weasel-like animal is native to central and southern Japan.
'The two premolars are clearly visible, and this characteristic indicates that it is a species of the Martes genus,' the study states.
4 The skeleton was found at the Todai-ji temple in Nara in 1429.
Getty Images
Using x-ray technology and radiocarbon dating, researchers found that the marten dated back to the 11th or 12th centuries.
The Todai-ji temple underwent heavy renovations at the time, according to Pen News.
Experts believe the animal entered the building and was trapped before it died and was mummified.
Pictures show the marten missing its forelegs, making it resemble a dragon.
4 Experts believe the animal entered the building and was trapped before it died and was mummified.
Office of the Shosoin Treasure House
Legend states that rain would descend upon the treasure house every time the skeleton's repository was opened – and during the study, researchers fought heavy downpours that made traveling from Tokyo to Nara difficult.
Mami Tsuru, a conservationist at the Shosoin Treasure House, told Pen News she's certain the skeleton is the same one recorded by the Todai-ji monk.
'The age determination has significantly increased the possibility that the mummy is the sun-dried dragon-looking object recorded in the document from the Muromachi Period,' the expert said.
Tsuru added, 'We believe this is a good example of how Shosoin has protected not only beautiful items, but also all the items inside the repository.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 hours ago
- Business Wire
Japan Delegation Concludes Visit to North Carolina to Explore Life Sciences Partnerships
ATLANTA--(BUSINESS WIRE)--A high-level Japanese delegation specializing in life sciences concluded a three-day visit to North Carolina (June 24–26), further strengthening ties between Japanese and U.S. leaders in the sector. Organized by the Japan External Trade Organization (JETRO) and co-organized by the Economic Development Partnership of North Carolina (EDPNC), the Research Triangle Regional Partnership, Greater Winston-Salem, Inc., and the Charlotte Regional Business Alliance, the visit included tours of key facilities within North Carolina's thriving life sciences ecosystem. The delegation commenced its visit with a meeting with Governor Josh Stein, followed by a tour of the North Carolina Plant Sciences Building at North Carolina State University and the Biomanufacturing Training and Education Center (BTEC), where they explored academic–industry collaboration in workforce development. The group also visited Spark LS, a 109-acre advanced life science campus, FUJIFILM Diosynth Biotechnologies, and Astellas Gene Therapies. On the second day, the delegation visited the Innovation Quarter in Winston-Salem and toured the Wake Forest Institute for Regenerative Medicine (WFIRM) to gain insights into cutting-edge initiatives in regenerative medicine. Additional site visits included Winston Starts, Ricoh, Mercodia, and Charter Medical. The day concluded with a warm welcome from Mayor Allen Joines. On the final day, the delegation visited the North Carolina Research Campus in Kannapolis and toured the North Carolina Food Innovation Lab. They also visited Coddle Creek Capital and the University of North Carolina Nutrition Research Institute. The visit concluded at The Pearl, Charlotte's emerging hub for healthcare innovation and scientific advancement. JETRO looks forward to deepening its collaboration with the State of North Carolina, building on the growing momentum between Japan and the region in advanced technology sectors.
National Geographic
2 days ago
- National Geographic
Could T. rex swim? Kinda
Evidence suggests dinosaurs like tyrannosaurs were probably best suited to a version of the doggy paddle. Despite what's depicted in movies and books, the real Tyrannosaurus rex was likely an awkward swimmer at best. Illustration by Fotokita, Getty Images When Michael Crichton released the novel Jurassic Park in 1990, he included a terrifying chase through one of the park's ponds. Fictional paleontologist Alan Grant, looking after kids Lex and Tim, tries to sneak by a dozing Tyrannosaurus rex and motor across a lake away from the dinosaur. The T. rex follows, swimming after them like 'the biggest crocodile in the world.' The scene stood out so much that it's been revamped for the new movie Jurassic World: Rebirth. But while tyrannosaurs might swim in movies and books, could they swim in real life? Carnivorous dinosaurs are not generally thought of as good swimmers. During much of the 20th century, in fact, paleontologists wrongly assumed that herbivorous dinosaurs ran into rivers and lakes to avoid the jaws of T. rex, Allosaurus, and other predators. No one had found any direct evidence that such carnivores could swim. But the discovery of dinosaur swim tracks at fossil sites around the world have indicated that theropod dinosaurs—the group that contains T. rex, birds, and their relatives—were more aquatically adept than suspected and may have even done their own version of the doggy paddle. At one 200 million-year-old fossil site in southern Utah, paleontologists have found over 2,500 scratches and traces made by small carnivorous dinosaurs swimming across a Jurassic lake. Over 120 million years ago, a larger theropod dinosaur swam through the shallows in what's now La Rioja, Spain. Another fossil site found in La Rioja has even allowed paleontologists to begin distinguishing between different types of swimming traces left by theropods kicking through the water, indicating that swimming was not unusual for feathery, sharp-toothed dinosaurs. To date, no one has found swim traces from a tyrannosaur. Paleontologists have found some rare tyrannosaur footprints, but not direct evidence of swimming. Still, University College London paleontologist Cassius Morrison notes, today, 'the majority of animals can swim' even without specific aquatic adaptations, and the fossil evidence of other swimming theropods suggests that big tyrannosaurs could, too. The question is how they would have done it. (Could dinosaurs swim? This fossil revives an age-old debate.) What did tyrannosaur swimming look like? Mature T. rex were very large animals. The biggest reached more than 40 feet in length and weighed over nine tons. Hefty as that is, however, nine tons is relatively light for such a big animal. The secret is that tyrannosaurs, like many dinosaurs, had a complex system of air sacs that branched out from its respiratory system and infiltrated the dinosaur's bones, just like in birds today. The air sacs allowed the dinosaur to be a little lighter without sacrificing strength, allowed the animal to breathe more efficiently, and, in the water, to float a little more easily. Magazine for all ages starting at $25/year The effects of dinosaur air sacs on swimming ability has been underscored by the bones of another giant carnivore and Jurassic Park alum—the croc-snouted, sail-backed Spinosaurus. While researchers debate how much time the paddle-tailed dinosaur spent in the water, fossil evidence suggests it had extra-dense bones. These heavier bones helped the dinosaur avoid being too buoyant, so that it could more easily use its muscle power to move through the water rather than actively working to stay submerged like we do when we go under water with lungs full of air. (Read more about Spinosaurus' penguin-like bones.) Spinosaurus had a skeleton adapted to dealing with the buoyancy of the air sacs, but other dinosaurs without such dense bones would have only been capable of a more unstable doggy paddle. Giant long-necked dinosaurs, for example, have been described as 'tipsy punters' that were relatively unstable in the water and could kick off the bottom but not swim the way a crocodile does. For the same reason, T. rex probably wouldn't be able to completely disappear beneath a lake's surface and burst out with open jaws, like in the movies. And even though the dinosaur's arms were too small and lacked the range of motion for a swim stroke, the same is true of many other carnivorous dinosaurs that left swim traces behind. The emerging picture is that T. rex was probably a strong, if unsteady, swimmer. The available evidence hints that a swimming T. rex would float near the surface of a body of water, using its powerful legs to kick along to cross. Did T. rex stalk prey in the water? T. rex's swimming abilities would have inevitably shaped its hunting strategy. In 2023, University of the Republic of Uruguay paleontologist R. Ernesto Blanco modeled how quickly T. rex could move through the water. He proposed that the tyrant lizard would have been too slow to catch prey like the duckbill Edmontosaurus and the ostrich-like Struthiomimus on dry land but could move faster while wading or swimming in shallow water. 'Depending on the water depth, T. rex would have different ways of propulsion,' Blanco says. In deep enough water, T. rex could have swum with most of its body under the surface, but more often the dinosaur likely waded or 'punted' off the bottom as the swim traces of other theropods indicate. Perhaps, Blanco suggested, T. rex preferred to hunt along shorelines where herbivores trying to escape in the water would have been slowed down and more vulnerable. Other experts are not yet convinced that T. rex preferred hunting and feeding along shorelines. The bulk of the evidence so far points to the reptiles ambushing prey on land and breaking any carcasses it could find down into splinters with its impressive jaw strength. Finding swim traces, tyrannosaur poop with aquatic animal remains, or other fossil evidence could help test the idea further. Nevertheless, splashing around in the water seems within the range of what T. rex could do during its Cretaceous days. Swimming—even awkwardly—was a useful ability in ancient lowland habitats that likely resembled the wetlands and swamps along the coast of the Gulf of Mexico today. Being able to cross such waterways and wet habitats would have been advantageous to big tyrannosaurs, and it's likely the dinosaurs did so at times. 'With current evidence available to us,' Morrison says, 'I would suggest that swimming may have been a way for Tyrannosaurus to navigate its environment.' The answer to why T. rex crossed the lake, in other words, may have been that lunch was on the other side.
Business Wire
2 days ago
- Business Wire
AN Venture Partners Announces Final Close of $200M Fund I
SAN FRANCISCO & TOKYO--(BUSINESS WIRE)--AN Venture Partners (ANV), a global biotech venture capital firm, today announced the final close of its first fund, AN Venture Partners I, LP, achieving its target of USD200 million (JPY29 billion), one of the largest Japan-focused biotech venture capital funds to date, and also one of the largest first-time biotech venture capital funds raised in the past year. More than 20 Limited Partners (LPs) have invested in the fund, led by Japan Investment Corporation, Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., MUFG Bank, Ltd. and Sumitomo Mitsui Banking Corporation. Ken Horne, Managing Partner of ANV, said: 'We are delighted to announce the successful close of our first fund at a record level and we want to thank all of our investors and advisors for their support. In particular, I want to thank my fellow investment partners Ari Nowacek, Takashi Futami, and Jun Hashimoto for all their effort and hard work.' 'We made our first investment in December 2023,' he continued, 'and everything we are seeing confirms our initial hypothesis that Japan represents an untapped source for innovative science. By identifying, investing and developing biotech companies based upon Japanese science into global success cases, ANV hopes to produce strong returns for its investors and to make a significant impact on growing the Japanese biotech ecosystem.' ANV was founded in 2022 in alliance with ARCH Venture Partners, one of the leading venture capital firms in the global biotechnology field. ANV will invest across all stages, from pre-proof-of-concept to advanced clinical stages, and sources, whether academia, big pharma spin-outs or combinations thereof, in biotech and biotech-related fields. The fund is interested in all modalities and disease spaces that can have significant clinical impact. ANV will focus on science originating in Japan but can invest globally as well. Given the current ecosystem in Japan, ANV will often take an active role in company-creation and work hand-in-hand with the founders to build global biotech companies. To date, the firm has invested in seven companies, including Capacity Bio, Typewriter Therapeutics, City Therapeutics, and Imbria Pharmaceuticals. City Therapeutics successfully completed a significant series A round and announced important strategic collaborations with large global pharma companies. Typewriter Therapeutics has been selected by the Japan Agency for Medical Research and Development (AMED) as a recipient of the 'Strengthening Program for Pharmaceutical Startup Ecosystem' and has gained access to financial support to expedite its development. A further three companies are currently in stealth mode. In addition to making its own investments, ANV is also working to advance the Japanese government's flagship policy of establishing the country as a leader in the field of biotechnology by 2030. In accordance with this initiative, the firm has been officially accredited as a certified venture capital by AMED. The ANV team is also collaborating with leading academics at major Japanese universities, the Cabinet office and a number of other government agencies to promote development of the biotech ecosystem in Japan. It has also brought the Science-to-Startup (S2S) event from the US to Japan, holding a successful first event in November 2024 that attracted almost 200 scientists, entrepreneurs and investors. The initiative aims to bridge cutting-edge life science research with practical applications. It strengthens Japan's biotech ecosystem by connecting researchers with global venture capital firms and creating opportunities to present commercialization ideas to investors and pharmaceutical companies. About AN Venture Partners ANV is a Tokyo and San Francisco-based multi-stage, global biotech venture capital firm specializing in bridging innovative science from Japan with the US start-up ecosystem. AN Venture Partners I, LP is a USD200 million fund that closed in June 2025. The firm was established in 2022 by a group of experienced venture capitalists from Japan and the United States, who have a wealth of experience building start-ups. ANV is committed to strengthening Japan's biotech ecosystem and founded initiatives such as Science2Startup Japan to accelerate ecosystem growth. For more information, please visit Appendix: Fund Overview Fund Name: AN Venture Partners I, LP Fund Size: USD200 million (approx. JPY29 billion) Backed by more than 20 Limited Partners (LPs) Fund Term: 10 years (launched December 2023) Investment Focus: Sector: Biotechnology and related fields Stage: Pre-seed to advanced clinical stages (flexible, stage-agnostic) Geography: Japanese startups or science-driven innovations from Japan Global startups leveraging Japanese technology Portfolio Companies: 7 investments (as of June 2025), including: Capacity Bio (Mitophagy platform) Typewriter Therapeutics (TPRT gene writing) City Therapeutics (RNAi drug discovery) Imbria Pharmaceuticals (Partial fatty acid oxidation inhibitors) Three stealth mode companies Portfolio Companies Capacity Bio, Inc. Mechanism: Mitophagy Overview: Developing a groundbreaking mitophagy treatment platform. The company's team has identified druggable surface receptors that induce mitophagy—a process that promotes the breakdown and regeneration of mitochondria, improving mitochondrial quality. Its pipeline addresses potential treatments for neuromuscular diseases, neurodegenerative diseases, autoimmune diseases, and rare genetic disorders. Typewriter Therapeutics, Inc. Mechanism: TPRT gene writing Overview: A startup aiming to commercialize mRNA-based gene therapies using its proprietary platform technology for targeted therapeutic gene insertion. Founded based on research achievements in transposons by one of its co-founders, Professor Emeritus Haruhiko Fujiwara of the University of Tokyo, who also serves as the company's senior researcher. Selected in December 2024 for AMED's "Strengthening Program for Pharmaceutical Startup Ecosystem." City Therapeutics, Inc. M echanism: RNAi Overview: A next-generation siRNA drug discovery company, co-founded with intellectual property from Professor Yukihide Tomari of the University of Tokyo and Professor Kotaro Nakanishi from Ohio State university. Completed a $135M Series A funding round in October 2024. Announced a strategic partnership with Bausch + Lomb in January 2025 and Biogen in May 2025, including milestone payments of up to USD485 million and up to USD1 billion respectively. Imbria Pharmaceuticals M echanism: Partial Fatty Acid Oxidation Inhibitor Overview: Developing treatments for non-obstructive hypertrophic cardiomyopathy (nHCM) and heart failure with preserved ejection fraction (HFpEF). Its lead candidate, ninerafaxstat, is a partial fatty acid oxidation inhibitor that shifts myocardial energy metabolism from fatty acid utilization to glucose utilization, improving energy efficiency. Completed a $58M Series B funding round in April 2025, primarily to advance Phase 2b clinical trials for nHCM.
